Huntington's disease: CoQ10 being investigated in trial to prevent deterioration.
This article was originally published in The Tan Sheet
Executive Summary
HUNTINGTON's DISEASE CLINICAL TRIAL WITH COENZYME Q10 will examine the ability of the dietary supplement and a drug regimen to prevent deterioration of motor skills associated with the fatal inherited disorder. Other symptoms of the progressive genetic disease include problems with coordination, cognitive difficulties and depression. Along with CoQ10, the study will evaluate Astra Merck's experimental drug remacemide. Patients will be randomized to CoQ10, remacemide, both or placebo for 30 months.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning